CPD In Practice

Guest: Dr. Jason Hitkari

Host: Dr. Chris Morrow

Producer: Craig Ferguson

Music: "Stand With Me" by Adrian Walther licensed via SoundStripe

Episode Timestamps

[00:00] – Introduction and episode overview

[00:29] – Guest introduction: Dr. Jason Hitkari

[01:05] – Declining fertility rates in Canada and BC

[03:54] – The rise of egg freezing and its exponential uptake

[05:20] – Elective vs. medical egg freezing (oncofertility)

[05:51] – Cost of egg freezing and lack of MSP coverage

[06:44] – CFAS guidelines on egg freezing: who and when

[07:32] – The primary care provider's role in egg freezing counselling

[08:05] – When to investigate infertility: age-dependent timelines

[09:46] – The basic infertility workup in primary care

[10:51] – AMH testing: what it is and how to interpret it

[11:53] – Pelvic ultrasound and tube assessment (HSG)

[13:44] – Who should be referred to a fertility specialist

[14:17] – Approaching the "fertility assessment" request in primary care

[15:44] – Overview of fertility treatments: IUI, IVF, and ICSI

[17:43] – Male fertility: lifestyle factors and semen analysis

[21:21] – BC's new MSP IVF funding: eligibility and coverage

[23:00] – The IVF waitlist and what patients can expect

[23:39] – How patients access the funded IVF program

[24:03] – Equity and access: financial, LGBTQ+, and legal barriers

[25:21] – Rural access to fertility care in BC

[27:05] – Key takeaways for primary care providers

[28:24] – Knowledge nugget: a brief history of fertility

[30:18] – Credits and CME information

Studies & Research Mentioned

Janecka M, Mill J, Basson MA, et al. Advanced paternal age effects in neurodevelopmental disorders—review of potential underlying mechanisms. Transl Psychiatry. 2017;7:e1019. doi:10.1038/tp.2016.294

Janecka M, Haworth CMA, Ronald A, et al. Paternal age alters social development in offspring. J Am Acad Child Adolesc Psychiatry. 2017;56(5):383–390. doi:10.1016/j.jaac.2017.02.006

Grossman DC, Curry SJ, Owens DK, et al. Screening for Ovarian Cancer: US Preventive Services Task Force Recommendation Statement. In: StatPearls. Rockville, MD: Agency for Healthcare Research and Quality; 2018. https://www.ncbi.nlm.nih.gov/books/NBK442158/

Practice Committee of the American Society for Reproductive Medicine. Fertility evaluation of infertile women: a committee opinion. Fertil Steril. 2021;116(5):1255–1265. https://www.asrm.org/practice-guidance/practice-committee-documents/fertility-evaluation-of-infertile-women-a-committee-opinion-2021/

© UBC Faculty of Medicine All Rights Reserved

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Guest: Dr. Randal Mason

Host: Dr. Chris Morrow

Producer: Craig Ferguson

Music: "Stand With Me" by Adrian Walther licensed via SoundStripe

Episode Timestamps

[00:00] – Introduction and episode overview

[01:09] – The scale of alcohol-related harms in BC and Canada

[02:21] – Why screening remains inconsistent in clinical practice

[04:10] – Screening at every point of care

[04:32] – Clinician discomfort and workflow barriers

[05:42] – New guidance on alcohol-related risk

[07:36] – Understanding risk thresholds: cancer and cardiovascular disease

[08:16] – Patient reactions and clarifying misconceptions

[09:03] – BC guidelines compared with Canadian guidelines

[10:28] – Screening tools: SASQ, AUDIT, AUDIT-C, DSM-5 criteria

[12:30] – Treatment approaches for high-risk drinking vs. diagnosed AUD

[13:21] – Challenges for rural and remote patients and providers

[15:13] – Considerations for Indigenous patients and culturally safe care

[20:34] – Using frameworks like the Five A's in clinical conversations

[21:20] – Closing remarks and preview of Part 2

[21:31] – Knowledge nugget: the history of alcohol and the origin of "toasting"

[22:10] – Credits and CME information

Studies & Research Mentioned

• Province of British Columbia. High‑Risk Drinking and Alcohol Use Disorder. BC Guidelines; 2024. Accessed January 29, 2026. https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/bc-guidelines/high-risk-drinking-and-alcohol-use-disorder

• Wood E, Bright J, Hsu K, et al; Canadian Alcohol Use Disorder Guideline Committee. Canadian guideline for the clinical management of high‑risk drinking and alcohol use disorder. CMAJ. 2023;195(40):E1364‑E1379. doi:10.1503/cmaj.230715. https://www.cmaj.ca/content/195/40/E1364

• Canadian Centre on Substance Use and Addiction (CCSA). Canada’s Guidance on Alcohol and Health. 2023. Accessed January 29, 2026. https://www.ccsa.ca/en/guidance-tools-resources/substance-use-and-addiction/alcohol/canadas-guidance-alcohol-and-health [

• World Health Organization. AUDIT: The Alcohol Use Disorders Identification Test: Guidelines for Use in Primary Care. 2nd ed. WHO; 2001. https://www.who.int/publications/i/item/WHO-MSD-MSB-01.6a

• U.S. Department of Veterans Affairs. Alcohol Use Disorders Identification Test – Consumption (AUDIT‑C). Updated March 2021. Accessed January 29, 2026. https://www.hepatitis.va.gov/alcohol/treatment/audit-c.asp

• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed, Text Revision (DSM‑5‑TR). American Psychiatric Association; 2022. Information and updates available at: https://www.psychiatry.org/psychiatrists/practice/dsm

• UBC Continuing Professional Development. Alcohol Use: Screening, Determining Risk, and Evidence‑Based Treatment. Accessed January 29, 2026.

https://ubccpd.ca/learn/learning-activities/course?eventtemplate=724-alcohol-use-screening-determining-risk-and-evidencebased-treatment

© UBC Faculty of Medicine All Rights Reserved

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Guest: Dr. Elizabeth Baerg Hall
Host: Dr. Chris Morrow
Producer: Craig Ferguson
Music: "Stand With Me" by Adrian Walther licensed via SoundStripe
Episode Timestamps
• [00:00] - Introduction and episode overview
• [02:03] - Life transitions and when ADHD becomes visible in adults
• [04:14] - How ADHD can be masked by structure and support systems
• [05:21] - Red flags for ADHD in primary care settings
• [08:54] - Who can diagnose ADHD and what tools are available
• [12:05] - The importance of impairment in diagnosis and avoiding overdiagnosis
• [16:36] - Common comorbidities: Anxiety, depression, and bipolar disorder
• [19:39] - ADHD and substance use disorder
• [21:26] - Barriers to diagnosis and treatment: Stigma and misconceptions about stimulants
• [24:07] - Inequities in access to care, including Indigenous patients
• [26:26] - Challenges for rural patients and older adults with ADHD
• [29:00] - Resources and support in BC: CADRA, Shared Care, and Skills for Success
• [30:56] - ADHD pathways and UBC CPD educational opportunities
• [32:59] - Closing remarks and conference information
• [33:52] - Knowledge nugget: The history of psychostimulants
Studies & Research Mentioned
• CADDRA – Canadian ADHD Resource Alliance. Canadian ADHD Practice Guidelines, 4.1 Edition. Toronto, ON: CADDRA; 2020. Accessed January 13, 2026. https://adhdlearn.caddra.ca/wp-content/uploads/2022/08/Canadian-ADHD-Practice-Guidelines-4.1-January-6-2021.pdf
• Centers for Disease Control and Prevention. Diagnosing ADHD. Updated 2024. Accessed January 13, 2026. https://www.cdc.gov/adhd/diagnosis/index.html
• The MTA Cooperative Group: A 14-Month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder (ADHD) . Arch Gen Psychiatry 1999;56:1073-1086.
• The MTA Cooperative Group: Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder (ADHD). Arch Gen Psychiatry 1999;56:1088-1096.
• Molina BSG, Kipp HL, Joseph HM, et al. Stimulant Diversion Risk Among College Students Treated for ADHD: Primary Care Provider Prevention Training. Acad Pediatr. 2020;20(1):119-127. doi:10.1016/j.acap.2019.06.002
• National Institute of Mental Health. The Multimodal Treatment of Attention Deficit Hyperactivity Disorder Study (MTA): Questions and Answers. Revised November 2009. National Institute of Mental Health website. Accessed January 13, 2026. https://www.nimh.nih.gov/funding/clinical-research/practical/mta/the-multimodal-treatment-of-attention-deficit-hyperactivity-disorder-study-mtaquestions-and-answers
• Ramtekkar UP, Reiersen AM, Todorov AA, Todd RD. Sex and age differences in attention-deficit/hyperactivity disorder symptoms and diagnoses: implications for DSM-V and ICD-11. J Am Acad Child Adolesc Psychiatry. 2010;49(3):217-28.e283.
(C) 2025 UBC Medicine Learning Network

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Endocrinologist Dr. Jordanna Kapeluto unpacks the evolving science of obesity and the role of GLP-1 medications like semaglutide. We explore obesity as a complex, chronic disease, the impact of weight bias in health care, and the promise and pitfalls of new treatments. From mechanisms of action to real-world outcomes, this conversation challenges assumptions and highlights the importance of compassionate, evidence-based care.   
Host: Dr. Chris Morrow
Producer:  Craig Ferguson
Music: "Stand With Me" by Adrian Walther licensed via SoundStripe
(C) 2025 UBC Medicine Learning Network
Episode Timestamps
[00:00] - Introduction and episode overview
[01:38] - Medical diagnosis of obesity: Why it is important to diagnose and treat
[02:27] - Evolution of our understanding of obesity and weight dynamics
[04:30] - Stigma surrounding obesity and patient experiences of weight bias affecting access to appropriate care or diagnostics
[06:14] - Defining and diagnosing obesity
[12:40] - Discussion on GLP-1 agonists
[15:45] - GLP-1 agonists and weight loss
[18:14] - GLP-1s in diabetes treatment
[18:42] - Criteria for using GLP-1s as a weight loss agent
[22:05] - GLP-1s: Downsides and barriers
[26:50] - Guidance for primary care providers on prescribing GPL-1s
[30:27] - Closing thoughts from Dr. Jordanna Kapeluto
[31:50] - Closing remarks from Dr. Chris Morrow on GLP-1 agonists
Studies & Research Mentioned
Rubino F, Bartolomucci A, Buse JB, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025;S2213-8587(24)00316-4. doi:10.1016/S2213-8587(24)00316-4
Palmer AB, Roshani R, McCormick JB, Fisher-Hoch SP, Below JE, North KE, Gordon-Larsen P. Excess Adiposity Without Obesity in a High-Risk Population. JAMA Netw Open. 2025 Oct 1;8(10):e2535194. doi: 10.1001/jamanetworkopen.2025.35194. PMID: 41042515; PMCID: PMC12495492.Drucker DJ. The GLP-1 journey: from discovery science to therapeutic impact. J Clin Invest. 2024;134(2):e175634. Published 2024 Jan 16. doi:10.1172/JCI175634 
Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem. 1992;267(11):7402-7405.
Quetelet A. Sur l'homme et le développement de ses facultés, ou Essai de physique sociale [A Treatise on Man and the Development of His Faculties]. Bachelier; 1835.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.